Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IVVD Invivyd	$0.78 -1.9%	$0.76	$0.35 ▼ $2.74	$93.81M	0.63	4.54 million shs	308,198 shs
RZLT Rezolute	$4.30 -0.3%	$3.95	$2.22 ▼ $6.19	$366.88M	1.04	587,660 shs	260,430 shs
TERN Terns Pharmaceuticals	$3.86 -3.6%	$3.32	$1.87 ▼ $11.40	$336.70M	-0.18	1.49 million shs	214,447 shs
UPXI Upexi	$2.63 -16.8%	$10.45	$1.90 ▼ $22.57	$99.92M	-0.3	953,505 shs	2.51 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IVVD Invivyd	+13.43%	+6.66%	-11.16%	+33.15%	-33.98%
RZLT Rezolute	-0.46%	+5.90%	+12.53%	+47.10%	+7.75%
TERN Terns Pharmaceuticals	-1.48%	0.00%	+32.89%	+36.99%	-40.03%
UPXI Upexi	-5.11%	-70.71%	-68.18%	+41.07%	-60.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IVVD Invivyd	3.3309 of 5 stars	3.6	3.0	0.0	2.6	3.3	0.6
RZLT Rezolute	2.9194 of 5 stars	3.6	1.0	0.0	3.7	4.2	0.0
TERN Terns Pharmaceuticals	4.3292 of 5 stars	3.3	2.0	4.1	3.3	3.3	0.6
UPXI Upexi	3.1848 of 5 stars	3.5	3.0	0.0	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IVVD Invivyd	3.25	Buy	$5.85	646.17% Upside
RZLT Rezolute	3.14	Buy	$11.83	175.51% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	305.32% Upside
UPXI Upexi	3.00	Buy	$16.00	508.37% Upside

Current Analyst Ratings Breakdown

Latest IVVD, RZLT, UPXI, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
5/28/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00
5/16/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IVVD Invivyd	$25.38M	3.71	N/A	N/A	$0.56 per share	1.40
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.07 per share	N/A
UPXI Upexi	$26M	3.84	N/A	N/A	$6.24 per share	0.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IVVD Invivyd	-$169.93M	-$1.20	N/A	7.13	N/A	-389.01%	-165.24%	-99.71%	8/13/2025 (Estimated)
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.09	N/A	N/A	N/A	N/A	-28.81%	-27.55%	8/4/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	7/8/2025 (Estimated)

Latest IVVD, RZLT, UPXI, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/8/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	-$0.26	+$0.03	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IVVD Invivyd	N/A	1.53	1.53
RZLT Rezolute	N/A	8.43	8.43
TERN Terns Pharmaceuticals	N/A	30.89	30.89
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IVVD Invivyd	70.36%
RZLT Rezolute	82.97%
TERN Terns Pharmaceuticals	98.26%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
IVVD Invivyd	25.40%
RZLT Rezolute	18.39%
TERN Terns Pharmaceuticals	1.50%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
RZLT Rezolute	40	85.52 million	69.79 million	Optionable
TERN Terns Pharmaceuticals	40	87.34 million	86.03 million	Not Optionable
UPXI Upexi	130	37.92 million	25.93 million	Optionable

IVVD, RZLT, UPXI, and TERN Headlines

Recent News About These Companies

Solana-Focused Upexi to Tokenize Shares; Added 56K SOL to Holdings

June 26 at 6:49 PM | finance.yahoo.com

Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell

June 26 at 8:46 AM | theglobeandmail.com

Upexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform

June 26 at 8:32 AM | quiverquant.comQ

Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell

June 26 at 8:00 AM | globenewswire.com

Solana Treasury Firm Upexi Falls After Insider Sales Filing

June 25 at 6:29 PM | bloomberg.com

News Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC Filings

June 25 at 6:29 PM | decrypt.coD

Upexi stock plunges after filing allows investors to sell shares

June 24 at 7:32 PM | in.investing.com

Upexi’s Solana treasury backfires with 60%+ dip as 43 million shares hit open market

June 24 at 7:32 PM | msn.com

Cantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to Overweight

June 18, 2025 | americanbankingnews.com

SOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption Narrative

June 17, 2025 | coindesk.com

Upexi, Inc. CSO Brian Rudick to Speak at ICR Conference on Public Market Crypto Strategies

June 17, 2025 | quiverquant.comQ

Upexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20th

June 17, 2025 | globenewswire.com

Upexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short Interest

June 17, 2025 | marketbeat.com

Cantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to "Overweight"

June 16, 2025 | marketbeat.com

Upexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ET

June 14, 2025 | seekingalpha.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?

June 11, 2025 | marketbeat.com

Upexi, Inc. Joins Webull Corporate Connect Service to Enhance Investor Engagement and Communication

June 11, 2025 | nasdaq.com

HODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable Report

June 10, 2025 | finance.yahoo.com

HODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable Report

June 10, 2025 | finance.yahoo.com

Upexi Joins Webull Corporate Connect Service Platform

June 9, 2025 | globenewswire.com

Upexi options begin trading on Nasdaq market

June 6, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, RZLT, UPXI, and TERN Company Descriptions

Invivyd NASDAQ:IVVD

$0.78 -0.01 (-1.87%)

As of 11:53 AM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Rezolute NASDAQ:RZLT

$4.28 -0.02 (-0.58%)

As of 11:54 AM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Terns Pharmaceuticals NASDAQ:TERN

$3.85 -0.15 (-3.80%)

As of 11:54 AM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Upexi NASDAQ:UPXI

$2.64 -0.53 (-16.61%)

As of 11:54 AM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time